AstraZeneca Pharma India Ltd. - Research Center
506820 ASTRAZEN Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | Mar ' 18 | |
|---|---|---|---|---|---|
| Sales | 805.60 | 813.56 | 831.81 | 728.29 | 571.00 |
| Operating profit | 86.17 | 135.47 | 120.69 | 71.30 | 46.29 |
| Interest | 0.95 | 1.09 | 1.14 | - | - |
| Gross profit | 99.99 | 147.22 | 132.54 | 87.59 | 58.54 |
| EPS (Rs) | 24.64 | 37.32 | 28.88 | 21.78 | 10.37 |
Annual
results in details
| Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | Mar ' 18 | |
|---|---|---|---|---|---|
| Other income | 14.76 | 12.84 | 12.99 | 16.29 | 12.25 |
| Stock adjustment | 14.47 | 2.95 | -39.21 | -1.38 | -51.00 |
| Raw material | 89.61 | 97.26 | 70.21 | 62.67 | 27.88 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 230.21 | 219.54 | 216.70 | 197.40 | 153.53 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | 45.21 | 55.76 | 79.80 | 72.81 |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 385.14 | 313.14 | 407.66 | 318.50 | 321.49 |
| Provisions made | - | - | - | - | - |
| Depreciation | 16.95 | 20.13 | 18.58 | 14.92 | 14.74 |
| Taxation | 21.44 | 33.79 | 41.75 | 18.22 | 17.89 |
| Net profit / loss | 61.59 | 93.30 | 72.21 | 54.44 | 25.91 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 10.70 | 16.65 | 14.51 | 9.79 | 8.11 |
| GPM (%) | 12.19 | 17.81 | 15.69 | 11.76 | 10.04 |
| NPM (%) | 7.51 | 11.29 | 8.55 | 7.31 | 4.44 |
Mutual Fund Selector
Find the fund that is right for you
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis